Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic disease, or aggressive subtypes that are more challenging to treat...
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in...
Guideline News CPG Mobile App The SITC Clinical Practice Guidelines (CPG) Mobile App is the first and only tool of its kind, offering direct, easy, portable access to SITC’s CPGs via phone or tablet. Highlighting key information from SITC’s published guidelines, the SITC CPG Mobile App...
The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions...
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as ‘living drugs,’ their toxicity...
Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has...
Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with...
A Message from the President Dear Colleagues, While the global coronavirus pandemic has held our attention since March, this edition of the President’s Message will focus on the greater mission that brings us all together. June is Cancer Immunotherapy Awareness Month™ , and so, first...
A Message from the President Dear Colleagues, The letter below was written before the COVID-19 pandemic transformed our lives. First, I hope all of you and your families are safe. For our members involved in delivery of health care, we are grateful for your courage, sacrifice and dedication...
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us